FTC Fights Shkreli's Bid To Duck Monopolization Case

Law360 (July 7, 2020, 9:12 PM EDT) -- The Federal Trade Commission and a contingent of states have urged a New York federal court not to toss their suit accusing former pharmaceutical executive Martin Shkreli and a company he founded of monopolizing the market for a lifesaving drug used to treat parasitic infections.

Enforcers filed oppositions on Monday to dismissal bids from Shkreli, Vyera Pharmaceuticals and the other defendants accused of blocking generic versions of Daraprim through restrictive supply agreements and then raising its price by 4,000%.

Shkreli is currently incarcerated for defrauding investors in another company he founded, Retrophin, and the opposition to his motion said that is...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!